Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO

INTEGRA LIFESCIENCES HOLDINGS CORP

2024-Q3 EPS reported -$0.34 revenue$1,167,881,000

Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
Neurosurgery organic sales -16% on shipping holds; Instruments +8.7%; Tissue Tech -3.7% organic, ex-Boston -9.4%.
FY2024 revenue guidance lowered to $1.609-1.619B (organic -1.7% to -1.0%); adjusted EPS guided $2.41-$2.49.
Mojdeh Poul named next president and CEO, effective Jan 6, 2025, succeeding retiring Jan De Witte.
Shipping holds releasing in line with expectations; Integra Skin production on pace for Q4 historical run rates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.